Clinical features of late‐onset Pompe disease: A prospective cohort study

The objective of this 12‐month study was to describe the clinical features of late‐onset Pompe disease and identify appropriate outcome measures for use in clinical trials. Assessments included quantitative muscle testing (QMT), functional activities (FAA), 6‐min walk test (6MWT), and pulmonary function testing (PFT). Percent predicted values indicated quantifiable upper and lower extremity weakness, impaired walking ability, and respiratory muscle weakness. Significant declines in arm and leg strength and pulmonary function were observed during the study period. The outcome measures were demonstrated to be safe and reliable. Symptom duration was identified as the best predictor of the extent of skeletal and respiratory muscle weakness. Muscle Nerve 38: 1236–1245, 2008

[1]  M. Ausems,et al.  Broad spectrum of Pompe disease in patients with the same c.-32-13T→G haplotype , 2007, Neurology.

[2]  R. McCarter,et al.  Reliable surrogate outcome measures in multicenter clinical trials of Duchenne muscular dystrophy , 2007, Muscle & nerve.

[3]  G. Herman,et al.  Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease. , 2006, The Journal of pediatrics.

[4]  Wuh-Liang Hwu,et al.  A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. , 2006, The Journal of pediatrics.

[5]  J. Hankinson,et al.  Interpretative strategies for lung function tests , 2005, European Respiratory Journal.

[6]  A. Pestronk,et al.  CINRG randomized controlled trial of creatine and glutamine in Duchenne muscular dystrophy , 2005, Annals of neurology.

[7]  W. Hop,et al.  Disease severity in children and adults with Pompe disease related to age and disease duration , 2005, Neurology.

[8]  W. Hop,et al.  Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients. , 2005, Brain : a journal of neurology.

[9]  T. Voit,et al.  Enzyme replacement therapy in classical infantile pompe disease: results of a ten-month follow-up study. , 2005, Neuropediatrics.

[10]  A. Janssens,et al.  Late-onset Pompe disease primarily affects quality of life in physical health domains , 2004, Neurology.

[11]  R. Howell,et al.  Pompe disease in infants and children. , 2004, The Journal of pediatrics.

[12]  W. Hop,et al.  Enzyme replacement therapy in late‐onset Pompe's disease: A three‐year follow‐up , 2004, Annals of neurology.

[13]  D. V. Leenen,et al.  Twenty‐two novel mutations in the lysosomal α‐glucosidase gene (GAA) underscore the genotype–phenotype correlation in glycogen storage disease type II , 2004, Human mutation.

[14]  W. Hop,et al.  The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature. , 2003, Pediatrics.

[15]  E. Hoffman,et al.  Collaborative translational research leading to multicenter clinical trials in Duchenne muscular dystrophy: the Cooperative International Neuromuscular Research Group (CINRG) , 2002, Neuromuscular Disorders.

[16]  B. Byrne,et al.  Acid alpha-glucosidase deficiency (glycogenosis type II, Pompe disease). , 2002, Current molecular medicine.

[17]  T. Voit,et al.  Sleep-disordered breathing and respiratory failure in acid maltase deficiency , 2001, Neurology.

[18]  A. Gulsvik,et al.  Fev(6) as a surrogate for FVC: authors should have included ROC-curve analyses. , 2001, American journal of respiratory and critical care medicine.

[19]  D. Escolar,et al.  Clinical evaluator reliability for quantitative and manual muscle testing measures of strength in children , 2001, Muscle & nerve.

[20]  L. Wilkins,et al.  Activate your online subscription , 2001, Neurology.

[21]  S. Spector,et al.  A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM , 2001, Neurology.

[22]  P. Laforêt,et al.  Juvenile and adult-onset acid maltase deficiency in France , 2000, Neurology.

[23]  M. Ausems,et al.  Phenotypic expression of late-onset glycogen storage disease type II: identification of asymptomatic adults through family studies and review of reported families , 2000, Neuromuscular Disorders.

[24]  P. Weiner,et al.  The cumulative effect of long-acting bronchodilators, exercise, and inspiratory muscle training on the perception of dyspnea in patients with advanced COPD. , 2000, Chest.

[25]  A. Amalfitano,et al.  Towards a molecular therapy for glycogen storage disease type II (Pompe disease). , 2000, Molecular medicine today.

[26]  S J Jay,et al.  Reference equations for the six-minute walk in healthy adults. , 2000 .

[27]  G. Criner,et al.  Prospective Randomized Trial Comparing Bilateral Lung Volume Reduction Surgery to Pulmonary Rehabilitation in Severe Chronic Obstructive Pulmonary Disease , 1999 .

[28]  A. Reuser,et al.  A diagnostic protocol for adult-onset glycogen storage disease type II , 1999, Neurology.

[29]  D L Sherrill,et al.  Reference equations for the six-minute walk in healthy adults. , 1998, American journal of respiratory and critical care medicine.

[30]  P. Paggiaro,et al.  Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease , 1998, The Lancet.

[31]  National-Isometric-Muscle-Strength-Database-Consor.  Muscular weakness assessment: use of normal isometric strength data. The National Isometric Muscle Strength (NIMS) Database Consortium. , 1996, Archives of physical medicine and rehabilitation.

[32]  A. Reuser,et al.  Genotype‐phenotype correlation in adult‐onset acid maltase deficiency , 1995, Annals of neurology.

[33]  T. Mets,et al.  Captopril treatment of chronic heart failure in the very old. , 1994, Journal of gerontology.

[34]  A. Miller,et al.  Lung function testing: selection of reference values and interpretative strategies. , 1992, The American review of respiratory disease.

[35]  S. Chinn,et al.  Portable liquid oxygen and exercise ability in severe respiratory disability. , 1992, Thorax.

[36]  C. Sherbourne,et al.  The MOS 36-Item Short-Form Health Survey (SF-36) , 1992 .

[37]  J. Miller,et al.  Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. , 1989, The New England journal of medicine.

[38]  P. Trend,et al.  Acid maltase deficiency in adults. Diagnosis and management in five cases. , 1985, Brain : a journal of neurology.

[39]  M. Brooke,et al.  Clinical trial in duchenne dystrophy. I. The design of the protocol , 1981, Muscle & nerve.

[40]  G. Herman,et al.  CHINESE HAMSTER OVARY CELL-DERIVED RECOMBINANT HUMAN ACID α -GLUCOSIDASE IN INFANTILE-ONSET POMPE DISEASE , 2009 .

[41]  ATS statement: guidelines for the six-minute walk test. , 2002, American journal of respiratory and critical care medicine.

[42]  J L Hankinson,et al.  Spirometric reference values from a sample of the general U.S. population. , 1999, American journal of respiratory and critical care medicine.

[43]  A. Reuser,et al.  Glycogenosis type II (acid maltase deficiency) , 1995, Muscle & nerve. Supplement.

[44]  Ware J.E.Jr.,et al.  THE MOS 36- ITEM SHORT FORM HEALTH SURVEY (SF- 36) CONCEPTUAL FRAMEWORK AND ITEM SELECTION , 1992 .

[45]  M. Province,et al.  Clinical trials in Duchenne dystrophy. Standardization and reliability of evaluation procedures. , 1984, Physical therapy.

[46]  L. F. Black,et al.  Maximal respiratory pressures: normal values and relationship to age and sex. , 1969, The American review of respiratory disease.